[{"address1": "177 East Colorado Boulevard", "address2": "Suite 700", "city": "Pasadena", "state": "CA", "zip": "91105", "country": "United States", "phone": "626 304 3400", "fax": "626 304 3401", "website": "https://arrowheadpharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.", "fullTimeEmployees": 609, "companyOfficers": [{"maxAge": 1, "name": "Dr. Christopher R. Anzalone Ph.D.", "age": 55, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 2104473, "exercisedValue": 1024000, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Patrick  O'Brien J.D., PharmD", "age": 60, "title": "COO, General Counsel & Secretary", "yearBorn": 1964, "fiscalYear": 2024, "totalPay": 998520, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James C. Hamilton M.D., MBA", "age": 46, "title": "Chief Medical Officer and Head of R&D", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 897694, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark M. Davis Ph.D.", "title": "Founder and Founder & Director of Insert Therapeutics Inc & Calando", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel J. Apel", "title": "Chief Financial Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Vincent  Anzalone CFA", "title": "Head of Investor Relations & VP", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Howard  Lovy", "title": "Director of Communications", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Bruce D. Given M.D.", "age": 70, "title": "Chief Medical Scientist", "yearBorn": 1954, "fiscalYear": 2024, "totalPay": 486308, "exercisedValue": 5934362, "unexercisedValue": 6159876}, {"maxAge": 1, "name": "Dr. Mark  Seefeld", "age": 70, "title": "Head of Toxicology & VP", "yearBorn": 1954, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Aaron  Tan", "title": "Head of Tax", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1748736000, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.arrowheadresearch.com/invest.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 16.46, "open": 16.72, "dayLow": 16.705, "dayHigh": 17.1, "regularMarketPreviousClose": 16.46, "regularMarketOpen": 16.72, "regularMarketDayLow": 16.705, "regularMarketDayHigh": 17.1, "payoutRatio": 0.0, "beta": 0.953, "forwardPE": -3.9834125, "volume": 1200463, "regularMarketVolume": 1200463, "averageVolume": 1874792, "averageVolume10days": 1683270, "averageDailyVolume10Day": 1683270, "bid": 16.74, "ask": 16.85, "bidSize": 2, "askSize": 8, "marketCap": 2321460992, "fiftyTwoWeekLow": 9.57, "fiftyTwoWeekHigh": 30.41, "priceToSalesTrailing12Months": 4.2579284, "fiftyDayAverage": 13.8085, "twoHundredDayAverage": 18.486176, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1967577344, "profitMargins": -0.26406, "floatShares": 120895883, "sharesOutstanding": 138100000, "sharesShort": 13242994, "sharesShortPriorMonth": 12530847, "sharesShortPreviousMonthDate": 1744675200, "dateShortInterest": 1747267200, "sharesPercentSharesOut": 0.0959, "heldPercentInsiders": 0.13018, "heldPercentInstitutions": 0.77255994, "shortRatio": 7.23, "shortPercentOfFloat": 0.1238, "impliedSharesOutstanding": 138100000, "bookValue": 4.949, "priceToBook": 3.3966458, "lastFiscalYearEnd": 1727654400, "nextFiscalYearEnd": 1759190400, "mostRecentQuarter": 1743379200, "netIncomeToCommon": -143968992, "trailingEps": -1.24, "forwardEps": -4.22, "lastSplitFactor": "1:10", "lastSplitDate": 1321488000, "enterpriseToRevenue": 3.609, "enterpriseToEbitda": -20.195, "52WeekChange": -0.3141575, "SandP52WeekChange": 0.119305134, "quoteType": "EQUITY", "currentPrice": 16.81, "targetHighPrice": 80.0, "targetLowPrice": 17.0, "targetMeanPrice": 44.0, "targetMedianPrice": 39.5, "recommendationMean": 1.86667, "recommendationKey": "buy", "numberOfAnalystOpinions": 14, "totalCash": 1095309056, "totalCashPerShare": 7.931, "ebitda": -97428000, "totalDebt": 740513984, "quickRatio": 4.977, "currentRatio": 5.147, "totalRevenue": 545209024, "debtToEquity": 108.227, "revenuePerShare": 4.305, "returnOnAssets": -0.05861, "returnOnEquity": -0.26224002, "grossProfits": 545209024, "freeCashflow": -6458500, "operatingCashflow": 61147000, "grossMargins": 1.0, "ebitdaMargins": -0.17870001, "operatingMargins": 0.70241, "financialCurrency": "USD", "symbol": "ARWR", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1749250352, "regularMarketTime": 1749240000, "exchange": "NMS", "messageBoardId": "finmb_203142", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.12637, "regularMarketPrice": 16.81, "marketState": "CLOSED", "earningsTimestamp": 1747080060, "earningsTimestampStart": 1754510400, "earningsTimestampEnd": 1754942400, "earningsCallTimestampStart": 1747081800, "earningsCallTimestampEnd": 1747081800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.24, "epsForward": -4.22, "epsCurrentYear": -0.17868, "priceEpsCurrentYear": -94.0788, "fiftyDayAverageChange": 3.0014992, "fiftyDayAverageChangePercent": 0.21736605, "twoHundredDayAverageChange": -1.6761761, "twoHundredDayAverageChangePercent": -0.09067187, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.9 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 756052200000, "shortName": "Arrowhead Pharmaceuticals, Inc.", "longName": "Arrowhead Pharmaceuticals, Inc.", "postMarketChangePercent": 1.07079, "postMarketPrice": 16.99, "postMarketChange": 0.18, "regularMarketChange": 0.35, "regularMarketDayRange": "16.705 - 17.1", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1874792, "fiftyTwoWeekLowChange": 7.24, "fiftyTwoWeekLowChangePercent": 0.7565308, "fiftyTwoWeekRange": "9.57 - 30.41", "fiftyTwoWeekHighChange": -13.6, "fiftyTwoWeekHighChangePercent": -0.4472213, "fiftyTwoWeekChangePercent": -31.415749, "displayName": "Arrowhead Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-06-07"}]